JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M202197200 on April 8, 2002

J. Biol. Chem., Vol. 277, Issue 24, 21549-21553, June 14, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/24/21549    most recent
M202197200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinberg, R. B.
Right arrow Articles by Steinmetz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinberg, R. B.
Right arrow Articles by Steinmetz, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Interfacial Exclusion Pressure Determines the Ability of Apolipoprotein A-IV Truncation Mutants to Activate Cholesterol Ester Transfer Protein*

Richard B. WeinbergDagger §, Rachel A. AndersonDagger , Victoria R. CookDagger , Florence Emmanuel||, Patrice Denèfle**, Alan R. TallDagger Dagger , and Armin Steinmetz§§¶¶

From the Departments of Dagger  Internal Medicine and § Physiology & Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, the || Cardiovascular Department, Gencell Division, ** Functional Genomics Center, Aventis Pharma, 94403 Vitry sur Seine, France, the Dagger Dagger  Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, and the §§ St. Nikolaus Stiftshospital Teaching Hospital, University of Bonn, D-56626 Andernach, Germany

Received for publication, March 6, 2002, and in revised form, April 5, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We used a panel of recombinant human apolipoprotein (apo) A-IV truncation mutants, in which pairs of 22-mer alpha -helices were sequentially deleted along the primary sequence, to examine the impact of protein structure and interfacial activity on the ability of apoA-IV to activate cholesterol ester transfer protein. Circular dichroism and fluorescence spectroscopy revealed that the secondary structure, conformation, and molecular stability of recombinant human apoA-IV were identical to the native protein. However, deletion of any of the alpha -helical domains in apoA-IV disrupted its tertiary structure and impaired its molecular stability. Surprisingly, determination of the water/phospholipid interfacial exclusion pressure of the apoA-IV truncation mutants revealed that, for most, deletion of amphipathic alpha -helical domains increased their affinity for phospholipid monolayers. All of the truncation mutants activated the transfer of fluorescent-labeled cholesterol esters between high and low density lipoproteins at a rate higher than native apoA-IV. There was a strong positive correlation (r = 0.790, p = 0.002) between the rate constant for cholesterol ester transfer and interfacial exclusion pressure. We conclude that molecular interfacial exclusion pressure, rather than specific helical domains, determines the degree to which apoA-IV, and likely other apolipoproteins, facilitate cholesterol ester transfer protein-mediated lipid exchange.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Apolipoprotein A-IV is a 46-kDa plasma glycoprotein (1) that is synthesized by the intestinal enterocytes of mammalian species (2) during lipid absorption (3). ApoA-IV1 enters circulation as a component of nascent chylomicrons (4, 5), but rapidly dissociates from their surface (5) and thereafter circulates primarily as a lipid-free protein (6). A broad spectrum of physiologic functions has been proposed for apoA-IV in human lipid metabolism (7, 8), including specific roles in intestinal lipid absorption (8), intravascular lipoprotein metabolism (9-12), cellular cholesterol efflux (13, 14) by interaction with the ABCA1 transporter (15, 16), and regulation of the activity of two key proteins involved in the process of reverse cholesterol transport:lecithin-cholesterol acyltransferase (17, 18) and cholesterol ester transfer protein (19, 20).

Cholesterol ester transfer protein (CETP) is a 74,000-dalton plasma protein that facilitates the exchange of non-polar lipids among circulating lipoproteins (21). CETP-mediated transfer of cholesterol esters from HDL to very low density lipoprotein is central to the process of reverse cholesterol transport (22). It is well established that lipoprotein lipid composition modulates CETP activity (23), but the role of apolipoproteins is less clear. In studies that used lipid emulsions as model lipoproteins, apolipoproteins A-I, A-II, A-IV, and E stimulated CETP-catalyzed lipid exchange equally well (20, 24, 25). However, studies that assayed CETP activity using native lipoproteins found that apoA-IV may have distinct concentration-dependant effects on CETP-catalyzed lipid exchange between HDL and LDL (26) and among HDL subfractions (19, 27).

Although like all apolipoproteins, apoA-IV has a high content of amphipathic alpha -helical structure (28, 29), the amphipathic helices in apoA-IV are very hydrophilic (29), are predominantly of the Y-class (30) and are incapable of deeply penetrating lipid monolayers (31, 32). With increasing surface pressure, these helices are sequentially excluded from the interface (33, 34). Consequently, the interaction of apoA-IV with lipoproteins is very labile and is sensitive to interfacial pressure (35). We have proposed that these properties enable apoA-IV to act as a barostat which maintains lipoprotein surface pressure within a critical range required for optimal activity of lipolytic enzymes and transfer proteins (33, 36, 37). In this regard, apoA-IV possesses dynamic interfacial properties that are optimal for stabilizing surface tension and lipid packing at expanding lipid/aqueous interfaces (34).

Using a panel of recombinant human apoA-IV truncation mutants, Emmanuel et al. (38) found that a specific alpha -helical domain located between residues 117 and 160 determines the catalytic efficiency of apoA-IV in the lecithin:cholesterol acyltransferase reaction. Given the impact of distinctive alpha -helical domains in determining the interfacial properties of apoA-IV, and given the importance of interfacial phenomena in the regulation of the CETP reaction (36), we have used this same panel of truncation mutants to examine the impact of alpha -helical structure, protein conformation, and interfacial activity on the ability of apoA-IV to modulate CETP-catalyzed cholesterol ester transfer between HDL and LDL.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Lipids-- Egg phosphatidylcholine and cholesterol oleate (Sigma) were dissolved in high performance liquid chromatography grade chloroform (Aldrich, Milwaukee, WI) and stored under nitrogen at -20 °C. Phospholipid concentration was determined by phosphorous analysis (39). The self-quenching fluorescent cholesterol ester analog NBDCE was obtained from Molecular Probes (Eugene, OR). Lipids were >99% pure by TLC on silica gel.

Lipoproteins, Apolipoproteins, and Cholesterol Ester Transfer Protein-- LDL and HDL were isolated from human plasma by sequential flotation at 1.019-1.063 and 1.125-1.25 g/ml, respectively, and dialyzed against 10 mM Tris, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.025% sodium azide. Human apoA-I was isolated from HDL (40). Human apoA-IV was isolated from donors homozygous for the A-IV-1 and A-IV-2 alleles (41). Recombinant human apoA-IV truncation mutants were created by site-directed mutagenesis of a DNA construct containing the human apoA-IV coding sequence, followed by expression in Escherichia coli (38). Recombinant human CETP was produced in a Chinese hamster ovary cell line expressing a cloned human CETP cDNA; the specific activity of recombinant CETP, as assayed by the transfer of 14C-cholesterol ester from HDL to LDL, was identical to plasma CETP (42). Protein concentration was determined with bicinchoninic acid (43). All preparations were homogeneous by SDS-PAGE. Mean molecular hydrophobicities and helical hydrophobic moments of recombinant apoA-IV truncation mutants were calculated using a consensus hydrophobicity scale (44).

Circular Dichroism Spectroscopy-- Circular dichroism studies were performed on a Jasco J-720 Spectropolarimeter. Spectra of apolipoproteins at 3 µM in 50 mM Tris, pH 7.4, 1 mM EDTA, 0.02% sodium azide were recorded at 25 °C from 190 to 260 nm using a 1-mm thermostated cell, 1-mm spectral bandwidth, and 2-s time constant. Buffer blanks were digitally subtracted. Percent alpha -helicity was calculated as previously described (28). Thermal denaturation studies were performed by monitoring ellipticity at 222 nm as a function of temperature from 20 to 65 °C. The enthalpy of denaturation, Delta HD, and the thermal denaturation midpoint, Tm, were determined from the slope of plots of Delta G versus 1/T (45).

Fluorescence Spectroscopy-- Fluorescence studies were performed on an SLM 8000C spectrofluorometer. Spectra of apolipoproteins at 3 µM in 50 mM Tris, pH 7.4, 1 mM EDTA, 0.02% sodium azide were recorded at 25 °C from 290 to 370 nm using a 1-cm cell with excitation at 280 nm, 1-s integration, and 4-nm slits on excitation and emission monochromators. Spectra were excitation corrected by reference to a rhodamine quantum counter, and corrected for scatter and Raman emission by digital subtraction of buffer blanks. Chemical denaturation studies were performed by addition of buffered 6 M guanidinium hydrochloride. Quenching studies were performed by addition of buffered 6 M KI; Stern-Volmer quenching constants, Kq, were obtained from plots of Io/I versus [KI]; fractional tryptophan exposure was calculated as Kq(apolipoprotein)/Kq(N-acetyltryptophanamide) (46).

Determination of Interfacial Exclusion Pressure-- The interfacial exclusion pressure (Pi ex) of recombinant apolipoproteins at the phospholipid/water interface was determined using a KSV 5000 Langmuir Film Balance (KSV Instruments, Helsinki, Finland), as previously described (33, 36). Egg phosphatidylcholine monolayers were spread at the air/buffer interface at initial pressures (Pi i) of 5-30 mN/m and then apolipoproteins were injected into the subphase to give a final concentration of 50 µg/dl, which had been previously determined to yield saturating binding to the interface. The increase in interfacial pressure was then monitored by a Wilhelmy plate until it reached a stable plateau (Delta Pi ). Pi ex was determined by extrapolation of Delta Pi versus Pi i. The precision of the interfacial pressure measurements was ±0.1 mN/m.

Fluorescent Cholesterol Ester Transfer Assay-- Fluorescent cholesterol ester transfer assays were performed using an SLM 8000C spectrofluorometer equipped with a thermostated cell holder. Recombinant HDL (rHDL) containing apoA-I, egg phosphatidylcholine, cholesterol oleate, and the self-quenching fluorescent cholesterol ester analog NDBCE were prepared by the method of Pittman et al. (47). Reaction mixtures containing NBDCE-labeled rHDL (0.1 mg/ml), LDL (1 mg/ml), apolipoproteins (5 µM), and recombinant human CETP (5 µg) in a final volume of 150 µl were incubated at 37 °C in a 3 × 3-mm magnetically stirred microcuvette, and the fluorescence intensity at 535 nm was monitored for 30 min with excitation at 465 nm, a 1-s integration rate, and 4-nm monochromator slits. Transfer rate constants were calculated from the slope of a linear regression of time versus ln(Imax - Ix), where Imax is the maximal fluorescence intensity and Ix is the fluorescence intensity at time X.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Calculated Hydrophobic Properties of Recombinant ApoA-IV Truncation Mutants-- Recombinant human apoA-IV (r-AIV) and a panel of recombinant apoA-IV truncation mutants in which pairs of 22-mer alpha -helices were sequentially deleted along the primary sequence from the amino to carboxyl terminus were expressed in E. coli (38). Although the calculated mean hydrophobicities, <H>, and mean helical hydrophobic moments, <µ>, of the deleted segments varied considerably, their deletion had a negligible impact on the hydrophobic properties of the remaining molecule (Table I).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Properties of the amphipathic helices in recombinant human apo A-IV and recombinant apo A-IV truncation mutants

Spectroscopic Studies-- Circular dichroism spectra of r-AIV revealed a mean residue ellipticity of 16,649 deg cm2/dmol at 222 nm, which corresponds to 50% alpha -helical structure (Table II). Thermal denaturation of r-AIV yielded an enthalpy of denaturation, Delta HD, of 70.8 kcal/mol with a transition midpoint at 50.3 °C. These parameters are similar to those obtained for native human apoA-IV-1 (28, 31, 45). Likewise, fluorescence spectroscopy of r-AIV revealed several features characteristic of human apoA-IV (28, 46). 1) The fluorescence emission of its single tryptophan was blue shifted to 328 nm. 2) Tryptophan fluorescence was resistant to iodide quenching, indicating that the tryptophan resides in a hydrophobic and/or negatively shielded environment. 3) Chemical denaturation induced a multiphasic red-shift in the wavelength of maximum fluorescence emission (data not shown) and an increase in relative quantum yield (Imax/Io) at the denaturation midpoint (Table II). Together these findings suggest that the secondary structure, conformation, and molecular stability of r-AIV are identical to that of native human apoA-IV.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Spectroscopic and thermodynamic properties of human apo A-IV and recombinant apo A-IV truncation mutants

ApoA-IV truncation mutants were much more sensitive to thermal denaturation, as evidenced by Delta HD values that were 19.6-51.0 kcal/mol lower than either native or the parent recombinant apoA-IV. Interestingly the alpha -helicity of all the truncation mutants was higher, perhaps reflecting recruitment of some local secondary structure with disruption of ordered folding. The tryptophan fluorescence emission in all the deletion mutants was red-shifted compared with native and r-AIV, although iodide accessibility was lower. Moreover, none of the truncation mutants displayed the increase in quantum yield with denaturation that is a signature of native human apoA-IV (28, 46). Taken together, these findings demonstrate that deletion of any of the alpha -helical domains in apoA-IV significantly disrupts its tertiary structure and impairs its molecular stability.

Exclusion Pressure at the Lipid/Water Interface-- Examination of the binding of r-AIV to egg phosphatidylcholine monolayers revealed that r-AIV was excluded from the lipid/water interface at pressures above 34.3 mN/m. In comparison, the exclusion pressure was 27.0 mN/m for native human apoA-IV-1, 30.8 mN/m for native apoA-IV-2, and 33.0 mN/m for apoA-I, as previously noted (33). The higher interfacial exclusion pressure of r-AIV relative to the native apolipoproteins could be a consequence of the presence of a hydrophobic MRGS(H)6 decapetide at its amino terminus, which was added to the recombinant construct to facilitate purification (38). Comparison of the interfacial exclusion pressure of the recombinant apoA-IV truncation mutants with r-AIV yielded the surprising finding that, with the exception of the Delta h1-2 and Delta h9-10 mutants, deletion of amphipathic alpha -helical domains increased the interfacial exclusion pressure (Fig. 1). There was no consistent relationship between either the hydrophobic properties of the excluded helices or the alpha -helicity of the remaining molecule and the interfacial exclusion pressure, although deletion of the exclusively Y class helices (30) near the COOH terminus yielded proteins with the highest surface activity.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Difference in the water/phosphatidylcholine interfacial exclusion pressure of recombinant apoA-IV truncation mutants compared with the parent recombinant apoA-IV, for which the exclusion pressure was 34.3 mN/m.

Effect on the Rate of CETP-mediated Cholesterol Ester Transfer-- Incubation of NDBCE-labeled rHDL with a 10-fold excess of LDL produced little change in fluorescence intensity; however, in the presence of CETP, transfer of the probe from the recombinant HDL to LDL caused a rise in fluorescence emission. The transfer rate constant in the presence of the common human apoA-IV-1 isoprotein was 2.22 × 10-3 s-1, for the variant human apoA-IV-2 isoprotein it was 2.59 × 10-3 s-1, and for r-AIV it was 2.92 × 10-3 s-1. In the presence of recombinant apoA-IV truncation mutants in the reaction mixture, the transfer rate constant varied between 2.45 and 3.29 × 10-3 s-1. Multiple factor correlation analysis identified no significant relationship between the transfer rate constants and any of the spectroscopic parameters, but a strong correlation was found between the transfer rate constants and interfacial exclusion pressure (r = 0.790, p = 0.002) (Fig. 2).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 2.   Rate constant for the transfer of NBD-labeled cholesterol esters from HDL to LDL versus interfacial exclusion pressure for human apoA-IV-1, human apoA-IV-2, recombinant apoA-IV, apoA-IV truncation mutants, and human apoA-I. The regression line is y = 0.08696x - 0.02111; r = 0.790; p = 0.002.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In solution, apoA-IV adopts a loosely folded "molten globule" conformation, in which the hydrophobic faces of its multiple amphipathic alpha -helices face inwards toward the interior of the molecule (28, 46). Our present findings demonstrate that these repeated alpha -helices collectively and cooperatively contribute to the molecular stability of apoA-IV in solution, for deletion of even short helical segments disrupts its tertiary conformation and significantly destabilizes the molecule. This is further suggested by the observation that these same deletions disrupt the otherwise strong self-association of apoA-IV (38). Interestingly, conformational destabilization of apoA-IV was associated with induction of additional alpha -helical structure, probably as a consequence of coil right-arrow helix transformations in regions of random coil structure, as occurs when it binds to phospholipid vesicles (31), or possibly because of altered self-association. Paradoxically, destabilization of the tertiary structure of the apoA-IV truncation mutants increased their interfacial exclusion pressure, perhaps because apoA-IV must unfold before it can fully adsorb to lipid/water interfaces (31, 33), or perhaps because destabilization of apoA-IV in solution increases the free energy gradient for its adsorption to the hydrophobic interface.

The data from this unique panel of apoA-IV truncation mutants do not support a role of specific helical domains in activating CETP. However, the observation of a relationship between interfacial exclusion pressure and cholesterol ester transfer rate sheds additional light on the biophysical role of apolipoproteins in the CETP reaction. CETP catalyzes the movement of non-polar lipids between lipoproteins along chemical concentration gradients (21, 23). Apolipoproteins could modulate this process by: 1) controlling the physical interaction of CETP with the surface of acceptor and/or donor particles; 2) modulating the interfacial solubility and accessibility of cholesterol esters; and 3) stabilizing acceptor particles as they acquire additional core lipids.

Regarding the first mechanism, the exclusion pressure of a lipid transfer protein must be close to the pressure of donor and acceptor interfaces, so that its binding is reversible; otherwise it could bind too tightly and become "locked" on the interface. Indeed, the calculated pressure of the HDL3 surface is 33 mN/m (33) and the interfacial exclusion pressure of CETP is 31 mN/m (36). Thus, apolipoproteins could control the association of CETP with donor and acceptor lipoproteins by modulating surface pressure. For example, there is little lipid transfer between naked lipid emulsion particles with CETP alone (24, 25), for CETP binds tightly to both donor and acceptor particles (48). The presence of apolipoproteins with exclusion pressures higher than CETP enables it to dissociate from donor particles after cholesterol ester loading, and, especially, from expanding acceptor particles after cholesterol ester delivery. If such phenomena predominate, then the efficacy of apolipoproteins in activating or inhibiting CETP will be a function of both their exclusion pressure and their ambient concentration (26).

Regarding the second and third mechanisms, both the microsolubilization of membrane-free cholesterol and phospholipids (49) and the solubility of cholesterol esters in phospholipid monolayers (36) is a function of interfacial pressure. Thus, adsorption of apolipoproteins to acceptor and donor particles could facilitate loading/unloading of cholesterol ester molecules by optimizing their surface accessibility and buffering any changes in the chemical concentration gradient as the reaction proceeds. In this regard, the relationship between the interfacial exclusion pressure of apoA-IV truncation mutants and cholesterol ester transfer rate depicted in Fig. 2 is remarkably similar to the relationship between exclusion pressure and the ability of apolipoproteins to promote phospholipid efflux from free cholesterol-enriched fibroblasts shown in Fig. 6 in the paper by Gillote et al. (49). In addition, by reducing surface tension, adsorption of apolipoproteins to acceptor particles would minimize the free energy cost of expansion, analogous to the role of the insect protein Lp-III in stabilizing hemolymph high density lipophorin particles as they acquire diacylglycerol transported by the lipid transfer particle (50). If such phenomena predominate, then the efficiency with which apolipoproteins activate CETP will be directly proportional to their surface activity (25).

Given that a large fraction of apoA-IV circulates as a lipid-free apolipoprotein (6), and that both plasma apoA-IV levels (5, 51) and CETP activity (52) increase in the post-prandial period, it is possible that apoA-IV could modulate CETP activity in vivo. In this regard, the higher exclusion pressure and cholesterol ester transfer rate of the apoA-IV-2 isoprotein raise the question as to whether this variant increases CETP activity in vivo. Several population screening studies have observed lower HDL levels (53, 54), higher LDL levels (55, 56), and an increased LDL/HDL ratio (54) in individuals carrying an A-IV-2 allele, as would be expected with increased CETP activity (57). However, in the only population survey to directly measure CETP activity, von Eckardstein et al. (58) found lower CETP activity in apoA-IV-1/2 heterozygotes. Possibly, other apoA-IV genetic variants with altered interfacial properties (59) could influence CETP activity.

Finally, these data raise several caveats regarding the use of modified recombinant apolipoproteins in biological studies. First, they illustrate how minor modifications made to facilitate protein purification may have major structural and functional consequences. In this case, addition of a hydrophobic decapeptide to the amino terminus of the r-AIV construct significantly increased its surface binding affinity and its ability to activate CETP. Second, these data illustrate the need for a full biophysical characterization of recombinant apolipoproteins used to probe the function of local domains. Again, the amino-terminal modification of r-AIV appeared to have no affect on its solution structure as assessed spectroscopically, yet it had a major impact on its interfacial activity. Likewise, spectroscopic characterization of the deletion mutants, alone, provided no indication as to how their apparent structural destabilization could increase their catalytic efficacy in the CETP reaction. Failure to fully characterize the biophysical properties of modified recombinant apolipoproteins could also lead to erroneously attributing a specific biologic function to local structure, when in fact, it was determined by global properties, such as interfacial activity. In this regard, however, comparison of our data and that of Emmanuel et al. (38) supports their conclusion that helixes 5 and 6 (residues 117-160) in apoA-IV play a specific catalytic role in lecithin:cholesterol acyltransferase activation.

In summary using a panel of recombinant human apoA-IV truncation mutants, we have found a strong correlation between interfacial exclusion pressure and the ability to activate CETP. We conclude that molecular interfacial exclusion pressure, rather than specific helical domains, determines the degree to which apoA-IV, and most likely other apolipoproteins, facilitate CETP-mediated lipid exchanges.

    FOOTNOTES

* This work was supported in part by NHLBI National Institutes of Health Grant HL30897 and American Heart Association Grant-in-Aid 93-013660.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157. Tel.: 336-716-4638; Fax: 336-716-6376; E-mail: weinberg@wfubmc.edu.

¶¶ Recipient of a Heisenberg-Stipendium from the Deutsche Forschungsgemeinschaft.

Published, JBC Papers in Press, April 8, 2002, DOI 10.1074/jbc.M202197200

    ABBREVIATIONS

The abbreviations used are: apo, apolipoprotein; CETP, cholesterol ester transfer protein; HDL, high density lipoproteins; LDL, low density lipoproteins; NBDCE, 22-(N-(7-nitrobenz-2-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3b-linoleate; r-AIV, recombinant human apoA-IV.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Weinberg, R. B., and Scanu, A. M. (1983) J. Lipid Res. 24, 52-59[Abstract]
2. Weisgraber, K. H., Bersot, T. P., and Mahley, R. W. (1978) Biochem. Biophys. Res. Commun. 85, 287-292[CrossRef][Medline] [Order article via Infotrieve]
3. Hayashi, H., Nutting, D. F., Fujimoto, K., Cardelli, J. A., Black, D., and Tso, P. (1990) J. Lipid Res. 31, 1613-1625[Abstract]
4. Green, P. H., Glickman, R. M., Saudek, C. D., Blum, C. B., and Tall, A. R. (1979) J. Clin. Invest. 64, 233-242[Medline] [Order article via Infotrieve]
5. Green, P. H., Glickman, R. M., Riley, J. W., and Quinet, E. (1980) J. Clin. Invest. 65, 911-919[Medline] [Order article via Infotrieve]
6. Bisgaier, C. L., Sachdev, O. P., Megna, L., and Glickman, R. M. (1985) J. Lipid Res. 26, 11-25[Abstract]
7. Lefevre, M., and Roheim, P. S. (1984) J. Lipid Res. 25, 1603-1610[Medline] [Order article via Infotrieve]
8. Kalogeris, T. J., Rodriquez, M. D., and Tso, P. (1997) J. Nutr. 127, 537S-543S[Abstract/Free Full Text]
9. Weinberg, R. B., and Spector, M. S. (1985) J. Lipid Res. 26, 26-37[Abstract]
10. Weinberg, R. B., and Spector, M. S. (1986) Biochem. Biophys. Res. Commun. 135, 756-763[CrossRef][Medline] [Order article via Infotrieve]
11. Bisgaier, C. L., Sachdev, O. P., Lee, E. S., Williams, K. J., Blum, C. B., and Glickman, R. M. (1987) J. Lipid Res. 28, 693-703[Abstract]
12. Goldberg, I. J., Scheraldi, C. A., Yacoub, L. K., Saxena, U., and Bisgaier, C. L. (1990) J. Biol. Chem. 265, 4266-4272[Abstract/Free Full Text]
13. Steinmetz, A., Barbaras, R., Ghalim, N., Clavey, V, Fruchart, J. C., and Ailhaud, G. (1990) J. Biol. Chem. 265, 7859-7863[Abstract/Free Full Text]
14. Bielicki, J. K., Johnson, W. J., Weinberg, R. B., Glick, J. M., and Rothblat, G. H. (1992) J. Lipid Res. 33, 1699-1709[Abstract]
15. Fournier, N., Atger, V., Paul, J. L., Sturm, M., Duverger, N., Rothblat, G. H., and Moatti, N. (2000) Arterioscler. Thromb. Vasc. Biol. 20, 1283-1292[Abstract/Free Full Text]
16. Remaley, A. T., Stonik, J. A., Demosky, S. J., Neufeld, E. B., Bocharov, A. V., Vishnyakova, T. G., Eggerman, T. L., Patterson, A. P., Duverger, N. J., Santamarina-Fojo, S., and Brewer, H. B. (2001) Biochem. Biophys. Res. Commun. 280, 818-823[CrossRef][Medline] [Order article via Infotrieve]
17. Steinmetz, A., and Utermann, G. (1985) J. Biol. Chem. 260, 2258-2264[Abstract/Free Full Text]
18. Chen, C. H., and Albers, J. J. (1985) Biochim. Biophys. Acta 836, 279-285[Medline] [Order article via Infotrieve]
19. Lagrost, L., Gambert, P., Dangremont, V., Athias, A., and Lallemant, C. (1990) J. Lipid Res. 31, 1569-1575[Abstract]
20. Main, L. A., Ohnishi, T., and Yokoyama, S. (1996) Biochim. Biophys. Acta 29, 17-24
21. Tall, A. R. (1993) J. Lipid Res. 34, 1255-1274[Medline] [Order article via Infotrieve]
22. Bruce, C., Chouinard, R. A., Jr., and Tall, A. R. (1998) Annu. Rev. Nutr. 18, 297-330[CrossRef][Medline] [Order article via Infotrieve]
23. Lagrost, L. (1994) Biochim. Biophys. Acta 1215, 209-236[Medline] [Order article via Infotrieve]
24. Milner, T. G., Ko, K. W. S., Ohnishi, T., and Yokoyama, S. (1991) Biochim. Biophys. Acta 1082, 71-78[Medline] [Order article via Infotrieve]
25. Ohnishi, T., and Yokoyama, S. (1993) Biochemistry 32, 5029-5035[CrossRef][Medline] [Order article via Infotrieve]
26. Guyard-Dangremont, V., Lagrost, L., and Gambert, P. (1994) J. Lipid Res. 35, 982-992[Abstract]
27. Barter, P. J., Rajaram, O. V., Chang, L. B. F., Rye, K. A., Gambert, P., Lagrost, L., Ehnholm, C., and Fidge, N. H. (1988) Biochem. J. 254, 179-184[Medline] [Order article via Infotrieve]
28. Weinberg, R. B., and Spector, M. S. (1985) J. Biol. Chem. 260, 4914-4921[Abstract/Free Full Text]
29. Weinberg, R. B. (1987) Biochim. Biophys. Acta 918, 299-303[Medline] [Order article via Infotrieve]
30. Segrest, J. P., Jones, M. K., De, Loof, H., Brouillette, C. G., Venkatachalapathi, Y. V., and Anatharamaiah, G. M. (1992) J. Lipid Res. 33, 141-166[Abstract]
31. Weinberg, R. B., and Jordan, M. (1990) J. Biol. Chem. 265, 8081-8086[Abstract/Free Full Text]
32. Weinberg, R. B., Jordan, M., and Steinmetz, A. (1990) J. Biol. Chem. 265, 18372-18378[Abstract/Free Full Text]
33. Weinberg, R. B., Ibdah, J. A., and Phillips, M. C. (1992) J. Biol. Chem. 267, 8977-8983[Abstract/Free Full Text]
34. Weinberg, R. B., Cook, V. R., DeLozier, J. A., and Shelness, G. S. (2000) J. Lipid Res. 41, 1419-1427[Abstract/Free Full Text]
35. Weinberg, R. B. (1992) in Third International Symposium on Plasma High Density Lipoproteins and Atherosclerosis (Miller, N. E. , and Tall, A. R., eds) , pp. 89-98, Elsevier, New York
36. Weinberg, R. B., Cook, V. R., Kussie, P., and Tall, A. R. (1994) J. Biol. Chem. 269, 29588-29591[Abstract/Free Full Text]
37. Weinberg, R. B., Jones, J. B., Lacko, A. G., and Pritchard, P. H. (1995) Biochem. Biophys. Res. Commun. 211, 840-846[CrossRef][Medline] [Order article via Infotrieve]
38. Emmanuel, F., Steinmetz, A., Rosseneu, M., Brasseur, R., Gosselet, N., Attenot, F., Cuine, F., Seguret, S., Latta, M., Fruchart, J. C., and Denefle, P. (1994) J. Biol. Chem. 269, 29883-29890[Abstract/Free Full Text]
39. Bartlett, G. R. (1959) J. Biol. Chem. 234, 466-468[Free Full Text]
40. Shore, B., and Shore, V. (1969) Biochemistry 8, 4510-4516[CrossRef][Medline] [Order article via Infotrieve]
41. Weinberg, R. B., Hopkins, R. A., and Jones, J. B. (1996) Methods Enzymol. 263, 282-296[Medline] [Order article via Infotrieve]
42. Hesler, C. B., Swenson, T. L., and Tall, A. R. (1987) J. Biol. Chem. 262, 2275-2282[Abstract/Free Full Text]
43. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150, 76-85[CrossRef][Medline] [Order article via Infotrieve]
44. Eisenberg, D. (1984) Annu. Rev. Biochem. 53, 595-623[CrossRef][Medline] [Order article via Infotrieve]
45. Weinberg, R. B., Anderson, R. A., Cook, V. R., Emmanuel, F., Denefle, P., Hermann, M., and Steinmetz, A. (2000) J. Lipid Res. 41, 1410-1418[Abstract/Free Full Text]
46. Weinberg, R. B. (1988) Biochemistry 27, 1515-1521[CrossRef][Medline] [Order article via Infotrieve]
47. Pittman, R. C., Glass, C. K., Atkinson, D., and Small, D. M. (1987) J. Biol. Chem. 262, 2435-2442[Abstract/Free Full Text]
48. Ohnishi, T., Hicks, L. D., Oikawa, K., Kay, C. C., and Yokoyama, S. (1994) Biochemistry 33, 6093-6099[CrossRef][Medline] [Order article via Infotrieve]
49. Gillotte, K. L., Zaiou, M., Lund-Katz, S., Anantharamaiah, G. M., Holvoet, P., Dhoest, A., Palgunachari, M. N., Segrest, J. P., Weisgraber, K. H., Rothblat, G. H., and Phillips, M. C. (1999) J. Biol. Chem. 274, 2021-2028[Abstract/Free Full Text]
50. Ryan, R. O. (1990) J. Lipid Res. 31, 1725-1739[Medline] [Order article via Infotrieve]
51. Ostos, M. A., Lopez-Miranda, J., Marin, C., Castro, P., Gomez, P., Paz, E., Jimenez-Pereperez, J. A., and Perez-Jimenez, F. (2000) Atherosclerosis 153, 209-217[CrossRef][Medline] [Order article via Infotrieve]
52. Tall, A., Sammett, D., and Granot, E. (1986) J. Clin. Invest. 77, 1163-1172[Medline] [Order article via Infotrieve]
53. Kamboh, M. I., Iyengar, S., Aston, C. E., Hamman, R. F., and Ferrell, R. E. (1992) Hum. Biol. 64, 605-616[Medline] [Order article via Infotrieve]
54. Campos, H., Lopez-Miranda, J., Rodrigquez, C., Albajar, M., Schaefer, E. J., and Ordovas, J. M. (1997) Arterioscler. Thromb. Vasc. Biol. 17, 1074-1081[Abstract/Free Full Text]
55. Kamboh, M. I., Hamman, R. F., Iyengar, S., Aston, C. E., and Ferrell, R. E. (1991) Atherosclerosis 91, 25-34[CrossRef][Medline] [Order article via Infotrieve]
56. Von Eckardstein, A., Funke, H., Schulte, M., Erren, M., Schulte, H., and Assmann, G. (1992) Am. J. Hum. Genet. 50, 1115-1128[Medline] [Order article via Infotrieve]
57. Agellon, L. B., Walsh, A., Hayek, T., Moulin, P., Jiang, X. C., Shelansky, S. A., Breslow, J. L., and Tall, A. R. (1991) J. Biol. Chem. 266, 10796-10801[Abstract/Free Full Text]
58. VonEckardstein, A., Funke, H., Chirazi, A., Chen-Haudenschild, C., Schulte, H., Schonfeld, R., Kohler, E., Schwarz, S., Steinmetz, A., and Assmann, G. (1994) Arterioscler. Thromb. 14, 1114-1120[Abstract/Free Full Text]
59. Weinberg, R. B. (2002) Curr. Opin. Lipidol. 13, 125-134[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Biophys. JHome page
V. M. Bolanos-Garcia, A. Renault, and S. Beaufils
Surface Rheology and Adsorption Kinetics Reveal the Relative Amphiphilicity, Interfacial Activity, and Stability of Human Exchangeable Apolipoproteins
Biophys. J., March 1, 2008; 94(5): 1735 - 1745.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Lu, Y. Yao, X. Cheng, S. Mitchell, S. Leng, S. Meng, J. W. Gallagher, G. S. Shelness, G. S. Morris, J. Mahan, et al.
Overexpression of Apolipoprotein A-IV Enhances Lipid Secretion in IPEC-1 Cells by Increasing Chylomicron Size
J. Biol. Chem., February 10, 2006; 281(6): 3473 - 3483.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. B. Weinberg, V. R. Cook, J. A. Beckstead, D. D. O. Martin, J. W. Gallagher, G. S. Shelness, and R. O. Ryan
Structure and Interfacial Properties of Human Apolipoprotein A-V
J. Biol. Chem., September 5, 2003; 278(36): 34438 - 34444.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/24/21549    most recent
M202197200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weinberg, R. B.
Right arrow Articles by Steinmetz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weinberg, R. B.
Right arrow Articles by Steinmetz, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.